title: Severe cholestasis due to adalimumab in a Crohn's disease patient.
abstract: Elevation of liver biochemistry has been reported with anti-tumor necrosis factor agents, but overt liver failure rarely reported. Autoimmune hepatitis has been more commonly reported with infliximab than adalimumab (ADA). Our case, however, describes the first reported case of ADA-associated severe cholestatic injury. A 39-year-old female with Crohn's disease developed severe jaundice after initiation of ADA. All serologic tests and imaging studies were normal. Liver biopsy showed prominent pericentral canalicular cholestasis, without features of steatosis or sclerosing cholangitis, consistent with drug-induced cholestasis. The serum total bilirubin peaked at 280 μmol/L, and improvement was seen after 5 wk with eventual normalization of liver enzymes at 10 wk. Our case describes the first reported case of ADA-associated severe cholestatic liver disease and the first histopathologic examination of this adverse drug effect. Clinicians need to be aware of this potential drug-induced liver injury when prescribing this commonly used biologic medication.
authors.affiliation: Edward Kim, Brian Bressler, Eric M Yoshida, Division of Gastroenterology, University of British Columbia, Vancouver, Vancouver, BC V5Z 1M9, Canada.
authors.forename: Edward
authors.initials: E
authors.lastname: Kim
authors.forename: Brian
authors.initials: B
authors.lastname: Bressler
authors.forename: David F
authors.initials: DF
authors.lastname: Schaeffer
authors.forename: Eric M
authors.initials: EM
authors.lastname: Yoshida
keywords: Adalimumab; Anti-tumor necrosis factor agents; Cholestasis; Crohn’s disease; Drug-induced liver injury